Literature DB >> 19553566

Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages.

Jianhai Du1, Na Wei, Tongju Guan, Hao Xu, Jianzhong An, Kirkwood A Pritchard, Yang Shi.   

Abstract

In inflammatory diseases, tissue damage is critically associated with nitric oxide ((*)NO) and cytokines, which are overproduced in response to cellular release of endotoxins. Here we investigated the inhibitory effect of roscovitine, a selective inhibitor of cyclin-dependent kinases (CDKs) on (*)NO production in mouse macrophages. In RAW264.7 cells, we found that roscovitine abolished the production of (*)NO induced by lipopolysaccharide (LPS). Moreover, roscovitine significantly inhibited LPS-induced inducible nitric oxide synthase (iNOS) mRNA and protein expression. Our data also showed that roscovitine attenuated LPS-induced phosphorylation of IkappaB kinase beta (IKKbeta), IkappaB, and p65 but enhanced the phosphorylation of ERK, p38, and c-Jun NH(2)-terminal kinase (JNK). In addition, roscovitine dose dependently inhibited LPS-induced expression of cyclooxygenase-2 (COX)-2, IL-1beta, and IL-6 but not tumor necrosis factor (TNF)-alpha. Tetrahydrobiopterin (BH(4)), an essential cofactor for iNOS, is easily oxidized to 7,8-dihydrobiopterin (BH(2)). Roscovitine significantly inhibited LPS-induced BH(4) biosynthesis and decreased BH(4)-to-BH(2) ratio. Furthermore, roscovitine greatly reduced the upregulation of GTP cyclohydrolase-1 (GCH-1), the rate-limiting enzyme for BH(4) biosynthesis. Using other CDK inhibitors, we found that CDK1, CDK5, and CDK7, but not CDK2, significantly inhibited LPS-induced (*)NO production in macrophages. Similarly, in isolated peritoneal macrophages, roscovitine strongly inhibited (*)NO production, iNOS, and COX-2 upregulation, activation of NFkappaB, and induction of GCH-1 by LPS. Together, our data indicate that roscovitine abolishes LPS-induced (*)NO production in macrophages by suppressing nuclear factor-kappaB activation and BH(4) biosynthesis, which might be mediated by CDK1, CDK5, and CDK7. Our results also suggest that roscovitine may inhibit inflammation and that CDKs may play important roles in the mechanisms by which roscovitine attenuates inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553566      PMCID: PMC2740392          DOI: 10.1152/ajpcell.00138.2009

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  39 in total

Review 1.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

Review 2.  Regulation of the expression of inducible nitric oxide synthase.

Authors:  Hartmut Kleinert; Andrea Pautz; Katrin Linker; Petra M Schwarz
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

3.  Chronic myocardial hypoxia increases nitric oxide synthase and decreases caveolin-3.

Authors:  Y Shi; K A Pritchard; P Holman; P Rafiee; O W Griffith; B Kalyanaraman; J E Baker
Journal:  Free Radic Biol Med       Date:  2000-10-15       Impact factor: 7.376

4.  Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III.

Authors:  Koustubh Panda; Robin J Rosenfeld; Sanjay Ghosh; Abigail L Meade; Elizabeth D Getzoff; Dennis J Stuehr
Journal:  J Biol Chem       Date:  2002-06-04       Impact factor: 5.157

Review 5.  Enzymatic function of nitric oxide synthases.

Authors:  P J Andrew; B Mayer
Journal:  Cardiovasc Res       Date:  1999-08-15       Impact factor: 10.787

6.  The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study.

Authors:  Jeannette Vásquez-Vivar; Pavel Martásek; Jennifer Whitsett; Joy Joseph; Balaraman Kalyanaraman
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

7.  Identification of proteins interacting with GTP cyclohydrolase I.

Authors:  Jianhai Du; Hao Xu; Na Wei; Bassam Wakim; Brian Halligan; Kirkwood A Pritchard; Yang Shi
Journal:  Biochem Biophys Res Commun       Date:  2009-05-12       Impact factor: 3.575

Review 8.  Novel small molecule cyclin-dependent kinases modulators in human clinical trials.

Authors:  Adrian M Senderowicz
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

9.  The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.

Authors:  Steven R Whittaker; Mike I Walton; Michelle D Garrett; Paul Workman
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

10.  Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity.

Authors:  Amy K Y Fu; Wing-Yu Fu; Alberto K Y Ng; Winnie W Y Chien; Yu-Pong Ng; Jerry H Wang; Nancy Y Ip
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

View more
  17 in total

1.  Inhibition of Cyclin-dependent Kinase 2 Signaling Prevents Liver Ischemia and Reperfusion Injury.

Authors:  Jin Xu; Zhengze Xue; Cheng Zhang; Yuan Liu; Ronald W Busuttil; Jiamin Zhang; Jerzy W Kupiec-Weglinski; Haofeng Ji
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

2.  Selective inhibition of CDK7 ameliorates experimental arthritis in mice.

Authors:  Yong Xia; Li-Ying Lin; Mei-Ling Liu; Zheng Wang; Hong-Hai Hong; Xu-Guang Guo; Guo-Quan Gao
Journal:  Clin Exp Med       Date:  2014-08-23       Impact factor: 3.984

3.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

Review 4.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

5.  Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase.

Authors:  Ru-Jeng Teng; Jianhai Du; Hao Xu; Ivane Bakhutashvili; Annie Eis; Yang Shi; Kirkwood A Pritchard; Girija G Konduri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-27       Impact factor: 5.464

6.  R-roscovitine reduces lung inflammation induced by lipoteichoic acid and Streptococcus pneumoniae.

Authors:  Arie J Hoogendijk; Joris J T H Roelofs; Janwillem Duitman; Miriam H P van Lieshout; Dana C Blok; Tom van der Poll; Catharina W Wieland
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

7.  Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.

Authors:  Nina Berberich; Bernd Uhl; Jos Joore; Ulrike K Schmerwitz; Bettina A Mayer; Christoph A Reichel; Fritz Krombach; Stefan Zahler; Angelika M Vollmar; Robert Fürst
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.

Authors:  Jiansong Fang; Pengyue Zhang; Yadi Zhou; Chien-Wei Chiang; Juan Tan; Yuan Hou; Shaun Stauffer; Lang Li; Andrew A Pieper; Jeffrey Cummings; Feixiong Cheng
Journal:  Nat Aging       Date:  2021-12-06

9.  Inhibition of Cyclin-Dependent Kinase 9 Downregulates Cytokine Production Without Detrimentally Affecting Human Monocyte-Derived Macrophage Viability.

Authors:  Brian J McHugh; Jillian Stephen; Calum T Robb; Sarah Fox; Tiina Kipari; Jennifer A Cartwright; Christopher Haslett; Rodger Duffin; Christopher D Lucas; Adriano G Rossi
Journal:  Front Cell Dev Biol       Date:  2022-05-26

10.  Role of tetrahydrobiopterin in resistance to myocardial ischemia in Brown Norway and Dahl S rats.

Authors:  Jianzhong An; Jianhai Du; Na Wei; Hao Xu; Kirkwood A Pritchard; Yang Shi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.